New York, June 1, 2026, 11:03 EDT
- RGNX traded at $6.97 late Monday morning, down about 0.6%, in a regular Nasdaq session.
- No fresh company release or SEC filing was listed in the last 24–48 hours; focus stayed on RGX-202 and cash runway.
- Biotech shares were weaker, with Sarepta also lower, keeping pressure on the Duchenne gene-therapy trade.
REGENXBIO Inc shares were little changed in Monday morning trading, down about 0.6% at $6.97 at 10:47 a.m. EDT, as the small-cap gene-therapy developer moved without a new company-specific catalyst. The stock traded between $6.85 and $7.15, with a market value of about $365 million.
Regular trading was under way on Nasdaq, whose U.S. market runs from 9:30 a.m. to 4 p.m. Eastern Time on standard weekdays. June 1 was not listed among Nasdaq’s 2026 market holidays.
The muted move matters because RGNX is still trading around older, but central, pipeline news. REGENXBIO’s latest investor release was a May 18 notice about healthcare investor conferences, while its investor filing page showed the latest 8-K and 10-Q entries dated May 14.
The main issue remains RGX-202, REGENXBIO’s experimental gene therapy for Duchenne muscular dystrophy, a muscle-wasting genetic disease. The company said on May 14 that the pivotal Phase III portion of its AFFINITY DUCHENNE study met its main goal, with 93% of patients reaching more than 10% microdystrophin expression at Week 12. Microdystrophin is a shortened muscle protein meant to stand in for dystrophin, which is missing or defective in Duchenne.
That keeps the stock tied to a regulatory question. REGENXBIO says it is preparing for potential accelerated approval in 2027; accelerated approval is an FDA pathway that can allow earlier clearance for serious diseases based on a surrogate endpoint, meaning a marker thought to predict clinical benefit rather than a direct measure of how a patient feels or functions.
Chief Executive Curran Simpson said in the May 14 update that the company had “positive momentum” and was pushing RGX-202 “toward potential BLA submission.” A BLA, or Biologics License Application, is the filing a company uses to seek FDA approval for a biologic drug. Regenxbio Inc
The balance sheet is part of the trade, too. REGENXBIO reported $150.5 million in cash, cash equivalents and marketable securities at March 31, down from $240.9 million at year-end, and posted a first-quarter net loss of $90.1 million. It said that cash should fund operations into early 2027, excluding possible partner payments or new financing.
The broader tape did not help. The SPDR S&P Biotech ETF, an exchange-traded fund that tracks a basket of biotech shares, fell about 3.1%; the iShares Nasdaq Biotechnology ETF lost about 2.1%. Sarepta Therapeutics, the closest Duchenne gene-therapy peer because of its approved Elevidys product, fell about 1.8%.
Sarepta remains the competitive reference point. Reuters reported last month that Wall Street was watching whether RGX-202’s safety profile could set it apart from Elevidys, which has faced liver-safety concerns, including two deaths from liver failure.
But the downside case is not hard to see. Leerink Partners analyst Mani Foroohar said the RGX-202 data looked “more mixed” than hoped, with adverse events and uncertainty over the FDA’s view likely to become a “source of debate.” REGENXBIO has said reported cases of subacute myocarditis and asymptomatic liver injury were managed and resolved, but gene-therapy stocks often trade hard on safety wording. Reuters
There is also recent regulatory scar tissue. In February, the FDA declined to approve REGENXBIO’s RGX-121 for Hunter syndrome, citing uncertainty around trial design and whether a surrogate endpoint was likely to predict clinical benefit; Simpson said at the time the company was concerned about the agency’s feedback.
For now, the stock’s action said little more than that investors are waiting. The next decisive move is more likely to come from FDA interaction, fresh clinical data or financing clarity than from Monday’s light trading tape.
